Filing Details
- Accession Number:
- 0001209191-24-002080
- Form Type:
- 4/A
- Zero Holdings:
- No
- Publication Time:
- 2024-01-23 17:00:49
- Reporting Period:
- 2023-07-11
- Accepted Time:
- 2024-01-23 17:00:49
- Original Submission Date:
- 2023-12-29
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1528115 | Annexon Inc. | ANNX | Pharmaceutical Preparations (2834) | 275414423 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1818525 | Ted Yednock | C/O Annexon, Inc. 1400 Sierra Point Pkwy, Bldg C, Ste 200 Brisbane CA 94005 | Evp & Chief Innovation Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2023-07-11 | 1,057 | $3.84 | 37,885 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2023-12-27 | 10,615 | $1.41 | 48,500 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2023-12-27 | 10,385 | $1.85 | 58,885 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-12-27 | 21,000 | $4.52 | 37,885 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 21,000 | Indirect | By Spouse |
Footnotes
- Late reporting of transaction being made as a result of an administrative oversight.
- The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs").
- This transaction was executed in multiple trades in prices ranging from $3.72 to $3.90, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- Includes 33,559 restricted stock units.
- The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted March 28, 2023.
- Column 5 is being amended to reflect the correct amount of securities beneficially owned following reported transaction.
- Reflects the correct amount of securities beneficially owned that was unintentionally omitted from the Form 4 filed December 29, 2023.
Billionaire Hedge Funds
